While IBC lesions may correspond to any of the major clinical subtypes of ductal adenocarcinoma (luminal A, luminal B, HER2 positive, or triple-negative (TNBC)), the more aggressive HER2-expressing and TNBC subtypes are over-represented among IBCs [5,6], with up to 40% of IBCs corresponding to the HER2 positive (HER2pos) subtype [7] and up to 30% designated as TNBC [8]. This evidence concerns the gene ERBB2 and invasive ductal breast carcinoma.